NASDAQ$CYRX
CryoPort Inc. · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
CryoPort reported record results for Q4 2020, marked by strategic acquisitions and strong performance in the cell and gene therapy market.
Cryoport's Q4 2020 was a transformational quarter with strong performance and continued momentum, especially in Cell and Gene Therapy. The acquisitions of MVE Biological Solutions and CRYOPDP expanded the company's global platform and capabilities. The company reported 36% organic growth in the fourth quarter.
- Increased regenerative medicine clinical trials supported to 528, compared to 436 at the end of 2019.
- Closed acquisitions of MVE Biological Solutions and CRYOPDP, expanding global platform.
- Established first jointly operated global logistics center in Osaka, Japan with CRYOPDP.
- Launched ESG program, marking first disclosure of ESG information.
Headline financials
Revenue & EPS history
CryoPort · Revenue · Quarterly
$48.4M
Forward guidance
Cryoport anticipates that 2021 will be another excellent year for the company.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
+2.2%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+8.5%
Avg return
30 days after
49%
28 / 57 earnings
Positive
+31.6%
Q4 2013
Best reaction
-33.8%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +19.4% | +33.2% | +58.2% | |
| Q4 2025 | +2.9% | -4.7% | +3.3% | |
| Q3 2025 | -8.2% | -7.4% | +3.5% | |
| Q1 2025 | +23.4% | +23.3% | +23.7% | |
| Q4 2024 | +30.6% | -7.1% | +5.7% | |
| Q3 2024 | -3.6% | -0.9% | -8.6% | |
| Q2 2024 | +3.9% | +10.0% | +9.8% | |
| Q1 2024 | -17.5% | -16.7% | -30.6% | |
| Q4 2023 | -12.3% | -7.3% | +10.3% | |
| Q3 2023 | +8.9% | +8.4% | +46.7% | |
| Q2 2023 | -0.2% | +1.2% | -5.0% | |
| Q1 2023 | +13.9% | +4.5% | -6.3% | |
| Q4 2022 | +13.7% | +9.9% | +15.3% | |
| Q3 2022 | -33.8% | -35.7% | -26.5% | |
| Q2 2022 | +6.8% | +5.2% | -16.1% | |
| Q1 2022 | -8.5% | -14.6% | -2.8% | |
| Q4 2021 | +9.3% | +7.0% | +1.9% | |
| Q3 2021 | -1.0% | -1.2% | -22.8% | |
| Q2 2021 | -1.5% | -3.6% | +2.9% | |
| Q1 2021 | +9.0% | +11.6% | -2.4% | |
| Q4 2020 | -0.7% | -11.7% | -12.5% | |
| Q3 2020 | +5.0% | +24.2% | +12.8% | |
| Q2 2020 | -2.0% | -5.0% | +55.5% | |
| Q1 2020 | +2.0% | +17.0% | +22.6% | |
| Q4 2019 | +2.1% | +0.8% | -11.9% | |
| Q3 2019 | +1.4% | +3.9% | +5.6% | |
| Q2 2019 | +19.7% | +24.5% | +2.3% | |
| Q1 2019 | +12.5% | +12.5% | +17.7% | |
| Q4 2018 | -0.6% | +6.6% | +22.3% | |
| Q3 2018 | -1.0% | -9.4% | -2.0% | |
| Q2 2018 | -1.6% | -14.7% | -6.5% | |
| Q1 2018 | +11.8% | +23.0% | +67.4% | |
| Q4 2017 | +3.8% | +6.4% | -7.0% | |
| Q3 2017 | -15.1% | -22.9% | -10.5% | |
| Q2 2017 | -2.0% | +3.6% | +28.6% | |
| Q1 2017 | +8.2% | +9.0% | +46.9% | |
| Q4 2016 | +23.7% | +9.0% | +23.7% | |
| Q2 2016 | -7.5% | — | — | |
| Q1 2016 | +10.2% | — | — | |
| Q4 2015 | -3.0% | — | — | |
| Q3 2015 | +7.5% | — | — | |
| Q2 2015 | -14.4% | — | — | |
| Q1 2015 | -2.2% | — | — | |
| Q4 2014 | +6.4% | — | — | |
| Q3 2014 | -5.6% | — | — | |
| Q4 2013 | +31.6% | — | — | |
| Q3 2013 | -8.0% | — | — | |
| Q2 2013 | +5.3% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | -3.1% | — | — | |
| Q3 2012 | -10.8% | — | — | |
| Q2 2012 | -8.0% | — | — | |
| Q1 2012 | -2.7% | — | — | |
| Q1 2010 | +11.2% | — | — | |
| Q3 2009 | +1.4% | — | — | |
| Q2 2009 | -2.8% | — | — | |
| Q1 2009 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro